Labeling of biotin with [166Dy]Dy/166Ho as a stable in vivo generator system

International Journal of Pharmaceutics

Volumn 255, Issue 1-2, 2003, Pages 129-138

  Ferro Flores, G ^a   De Murphy, C Arteaga ^b   Pedraza Lopez M ^b   Monroy Guzman F ^a   Melendez Alafort L ^c   Tendilla, J I ^a   Jimenez Varela R ^a  

^a INSTITUTO NACIONAL DE INVESTIGACIONES NUCLEARES   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MÉXICO   (Mexico)

Author keywords

Dysprosium 166 166Dy Dy 166Ho DTPA Biotin; Holmium 166; In vivo generator; Radiolabeled biotin; Targeted radiotherapy

Indexed keywords

AGAROSE; AVIDIN; BIOTIN; DYSPROSIUM; DYSPROSIUM 166; DYSPROSIUM DIETHYLENETRIAMINEPENTAACETIC ALPHA,OMEGA BIS(BIOCYTINAMIDE) DY 166; HOLMIUM; HOLMIUM 166; HOLMIUM DIETHYLENETRIAMINEPENTAACETIC ALPHA,OMEGA BIS(BIOCYTINAMIDE) HO 60; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; DTPA BIS BIOTIN; DTPA-BIS-BIOTIN; RADIOISOTOPE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DEVICE; DRUG DISTRIBUTION; DRUG LABELING; DRUG PURITY; DRUG STABILITY; DRUG SYNTHESIS; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; KIDNEY CLEARANCE; MOUSE; NEUTRON RADIATION; NONHUMAN; PH; PRIORITY JOURNAL; RADIOCHEMISTRY; RADIOISOTOPE DECAY; REACTOR; SERUM; TEMPERATURE; THIN LAYER CHROMATOGRAPHY; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; TISSUE DISTRIBUTION;

ANIMALS; BIOTIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; DRUG STABILITY; DYSPROSIUM; FEMALE; HOLMIUM; INJECTIONS, INTRAVENOUS; ISOTOPE LABELING; MICE; MICE, INBRED BALB C; PENTETIC ACID; RADIOISOTOPES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 0037436924     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00052-8     Document Type: Article

References (12)

1. 90Y -DOTA-Biotin J. Nucl. Med. 41:2000;131-140.
2. 99mTc -DTPA-bis-Biotin in rat AS-30D-hepatoma cells Nucl. Med. Biol. 30:2003;135-140.
3. Cremonesi M., Ferrari M., Chinol M., Stabin M.G., Grana C., Prisco G., Robertson C., Tosi G., Paganelli G. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients. Eur. J. Nucl. Med. 26:1999;110-120.
4. Ferro-Flores G., Ramírez F.M., Tendilla J.I., Pimentel G.G., Murphy C.A., Meléndez L., Ascencio J.A., Croft B.Y. Preparation and pharmacokinetics of samarium(III)-153-labeled DTPA-Biotin. Characterization and theoretical studies of the samarium (III)-152 conjugate. Bioconjug. Chem. 10:1999;726-734.
5. Ferro-Flores, G., Arteaga de Murphy, C., Villarreal, B.J.E., Pedraza, L.M., García, S.L., Tendilla, J.I., 2001. Development of targeted radiotherapy systems. In: Fifth Mexican Symposium on Medical Physics. AIP Conference Proceedings, vol. 593. pp. 63-70.
6. Grana C., Chinol M., Robertson C., Maceta C., Bartolomei M., De Cicco C., Fiorenza M., Gatti M., Cliceti P., Paganelli G. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br. J. Cancer. 86:2002;207-212.
7. Hymes J., Wolf B. Human biotinidase isn't just for recycling biotin. J. Nutr. 129:1999;485S-489S.
8. Knapp F.F., Mirzadeh S. The continuing important role of radionuclide generator systems for nuclear medicine. Eur. J. Nucl. Med. 21:1994;1151-1165.
9. Knox S.J., Goris M.L., Tempero M., Weiden P.L., Gentner L., Breitz H., Adams G.P., Axworthy D., Gaffigan S., Bryan K., Fisher D.R., Colcher D., Horak I.D., Weiner L.M. Phase II trial of yttrium-90-DOTA-Biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res. 6:2000;406-414.
10. Lambrecht R.M., Tomiyoshi K., Sekine T. Radionuclide generators. Radiochim. Acta. 77:1997;103-123.
11. 166Ho]Holmium in vivo generator Appl. Radiat. Isot. 46:1995;759-764.
12. Volkert W.A., Hoffman T.J. Therapeutic radiopharmaceuticals. Chem. Rev. 99:1999;2269-2292.